WO2004091642A1 - 関節炎の予防または治療剤 - Google Patents
関節炎の予防または治療剤 Download PDFInfo
- Publication number
- WO2004091642A1 WO2004091642A1 PCT/JP2004/005115 JP2004005115W WO2004091642A1 WO 2004091642 A1 WO2004091642 A1 WO 2004091642A1 JP 2004005115 W JP2004005115 W JP 2004005115W WO 2004091642 A1 WO2004091642 A1 WO 2004091642A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- plant
- salt
- food
- extract
- feed
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K10/00—Animal feeding-stuffs
- A23K10/30—Animal feeding-stuffs from material of plant origin, e.g. roots, seeds or hay; from material of fungal origin, e.g. mushrooms
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/163—Sugars; Polysaccharides
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7008—Compounds having an amino group directly attached to a carbon atom of the saccharide radical, e.g. D-galactosamine, ranimustine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Definitions
- the present invention relates to an agent for preventing or treating arthritis, and a food or drink, a food or drink additive, a feed and a feed additive for preventing or treating arthritis.
- Thunbergii Makino is a neighboring species of hydrangea, and is said to have been produced by breeding of hydrangea (Hydrangea macrophylla SER var. Acuminata) in the Edo period.
- This sweet tea or sweet tea extract has been used as a raw material for producing sweetening agents such as pills and oral fresheners.
- Aqueous extracts of sweet tea are used as sweeteners in liquid or powder form.
- the sweetening component is filodurcin.
- Sweet tea is known to have anticoccididium activity, antifungal activity, antiulcer activity, antiallergic activity, hypercholesterolemia inhibitory activity, antiperiodontal bacterial activity, antioxidant activity, etc. (2nd medicine) And Food Symposium Abstracts, 1999, p. 85). It is also known that the sweet tea extract exhibits a bile effect (Pharmaceutical Journal, 1994, Vol. 114, No. 6, p. 401-413). It is also known that sweet tea extract has an inhibitory effect on liver microsomal lipid peroxidation in vitro [Natural Medicines, 1995, Vol. 49, No. 1, p.
- a plant of a plant belonging to the genus Hydrangea or an extract of the plant is known to have a preventive or therapeutic effect on arthritis (WO 02/102396 pamphlet). It is also known that chondroitin sulfate, dalcosamine, and the like, which are constituents of cartilage, have a therapeutic effect on arthritis (Japanese Patent No. 2971579).
- a plant consisting of a plant belonging to the genus Hydrangea or an extract thereof, and a composition comprising a combination of an amino sugar or a salt thereof and Z or daricosaminodalican or a salt thereof are not known. It is not known that any substance has a synergistic preventive or therapeutic effect on arthritis. Disclosure of the invention,
- An object of the present invention is to provide a prophylactic or therapeutic agent for arthritis, or a food or drink, a food or drink additive, a feed or a feed additive for preventing or treating arthritis.
- the present invention relates to the following (1) to (27).
- a prophylactic or therapeutic agent for arthritis comprising a plant of a plant belonging to the genus Hydrangea or an extract of the plant, and an amino sugar or a salt thereof and / or glycosaminodalican or a salt thereof as an active ingredient.
- glycosaminodalican is chondroitin sulfate or a salt thereof, (1 ) The agent for preventing or treating arthritis according to any one of (4) to (4).
- glycosaminodalican is chondroitin sulfate or a salt thereof.
- a plant or a plant extract of a plant belonging to the genus Hydrangea and a feed or feed additive containing an amino sugar or a salt thereof and / or a daricosaminodalican or a salt thereof.
- a method for preventing or treating arthritis comprising administering a plant of a plant belonging to the genus Hydrangea or an extract of the plant, and an amino sugar or a salt thereof and Z or glycosaminodalican or a salt thereof.
- glycosaminodalican is chondroitin sulfate or a salt thereof.
- plants belonging to the genus Hydrangea include Hydrangea macrophylla Seringe; Ansa (Hydrangea macrophylla Seringe var.otaksa Makino); macrophyl la Seringe var.acuminata), Amatilla (Hvdrangea macrophylla Seringe var. Hydrangea sikokiana Maxim. la Seringe subsp.serrata Makino var.angustata Makino), and Amatiyah (Hydrange a macrophyl la Seringe var. Thunbergi i Makino) is preferably used.
- Hydrangea plants include plants belonging to the genus Hydrangea As long as it is used, any of a wild plant, a plant obtained by cultivation, a plant obtained by culture such as tissue culture, and the like may be used.
- Examples of the plant include leaves, flowers, branches, stems, fruits, roots, seeds, cultured cells or organs, sites of callus, and the like.
- various processed products obtained by physically or chemically or biologically treating these sites may be used.
- Examples of the physical or chemical treatment include drying such as sun drying and air drying, freeze-drying, pulverization, and extraction.
- the physical or chemical treatment is a dry treatment. , Freeze-dried, pulverized, extracted, etc.
- Examples of the biological treatment include fermentation, and examples of the biological treatment include fermentation.
- sweet tea obtained by subjecting Amatilla to a fermentation treatment and then drying is preferably used.
- the plant of the genus Hydrangea is referred to as the plant of the present invention.
- Examples of the plant extract of the present invention include substances that can be obtained from the plant by a method for extracting a substance having a preventive or therapeutic effect on arthritis from the plant, such as various solvent extractions and supercritical fluid extractions. .
- the solvent used for the solvent extraction may be any solvent, for example, an aqueous medium or an organic solvent, as long as it can extract a substance having a prophylactic or therapeutic effect on arthritis (hereinafter also referred to as an active ingredient). Further, the solvent may be used alone or as a mixed solvent obtained by combining a plurality of solvents.
- aqueous medium examples include water, an inorganic salt aqueous solution, a buffer, and the like, and water is preferred.
- water examples include tap water, distilled water, deionized water, pure water, and the like.
- Examples of the buffer include a phosphate buffer, a citrate buffer and the like.
- Examples of the inorganic salt in the aqueous inorganic salt solution include sodium chloride, potassium chloride, calcium chloride and the like.
- organic solvent examples include monohydric aliphatic alcohols such as methanol, ethanol, 1-propanol, 2-propanol, 1-butanol, and 2-butanol; dihydric aliphatic alcohols such as ethylene glycol and propylene glycol; and glycerol.
- Trihydric aliphatic alcohols such as alcohol, alkyl acetates such as methyl acetate and ethyl acetate, aliphatic ketones such as acetone and ethyl methyl ketone, aliphatic ethers such as dimethyl ether and dimethyl ether, hexane, Aliphatic hydrocarbons such as heptane and petroleum ether, alicyclic hydrocarbons such as cyclohexane, aromatic hydrocarbons such as toluene and benzene, chloroform, dichloromethane, 1,1,1,2-tetrafluoroethyl Halogenated aliphatic hydrocarbons such as tan, 1,1,2-trichloroethene, sesame oil, corn oil, Any solvent from which the active ingredient is extracted, such as edible oils and fats such as leaven oil and cottonseed oil, liquefied aliphatic hydrocarbons such as methane, ethane, propane, propylene, but
- the sole solvent is preferably an aqueous medium, an alcohol or an aliphatic ketone.
- an alcohol a monohydric aliphatic alcohol is more preferred, and ethanol is particularly preferred.
- Acetone is preferred as the aliphatic ketone.
- hydrous alcohol is preferable, hydrous monovalent aliphatic alcohol is more preferable, and hydrous ethanol is particularly preferable.
- the water content is preferably 70% (v / v) or less, more preferably 40% (v / v) or less.
- equipment used in ordinary solvent extraction such as a stirrer, ultrasonic generator, reflux extractor, Soxhlet extractor, homogenizer, and shaker, is used.
- the amount of the solvent used in the solvent extraction is not particularly limited. For example, 0.1 to 100 parts by weight, preferably 1 to 100 parts by weight of the solvent is added to 1 part by weight of the plant of the present invention.
- Perform using The extraction temperature is not particularly limited as long as the temperature is equal to or higher than the melting point of the solvent and equal to or lower than the boiling point, but is preferably 0 to 100, more preferably 20 to 90 for an aqueous medium, and 0 to 100 for an organic solvent. 0 is preferable, and 20 to 90 is more preferable.
- the extraction time is not particularly limited, but is preferably 1 minute to 1 week, more preferably 30 minutes to 1 day.
- a solid-liquid separation method such as sedimentation separation, cake filtration, clarification filtration, centrifugal filtration, centrifugal sedimentation, squeeze separation, filter press, or the like is used, and preferably, the extract is obtained by filtration and extracted. It may be a thing. Further, the extraction residue obtained by the solid-liquid separation method may be further extracted with an extraction solvent, and this may be used as an extract.
- the extractant fluid When performing supercritical fluid extraction (also referred to simply as supercritical extraction), the extractant fluid may be used alone, or a mixture of the extractant fluid and the entrainer may be used. Extractant fluids include carbon dioxide, ammonia, methanol, ethanol, isopropyl alcohol, ethane, propane, butane, pentane, hexane, dimethylbutane, benzene, dichlorodifluoromethane, dichlorofluoromethane, and trichlorofluoromethane.
- any supercritical fluid such as methane, dichlorotetrafluoromethane, trifluoromethyl methane, getyl ether, ethyl methyl ether, hexane, and dinitrogen monoxide may be used, but supercritical carbon dioxide is preferably used.
- a supercritical fluid also referred to as a supercritical gas
- Fluid in a state exceeding the critical pressure is defined as a critical temperature and a supercritical fluid.
- any of monohydric aliphatic alcohols such as methanol and ethanol, water, hydrated monohydric aliphatic alcohols, acetone and hexane can be used, and ethanol is particularly preferably used.
- the addition amount of the entrainer is preferably from 0.1 to 50% (w / w), more preferably from 1 to 20% (w / w).
- the amount of the extractant fluid used for the supercritical fluid extraction is not particularly limited, but is, for example, 5 to 100 parts by weight, preferably 20 to 5 parts by weight, per 1 part by weight of the plant of the present invention. 0 parts by weight of extractant fluid is used. Also, the extractant fluid may be circulated as needed.
- the amount of entrainer used for supercritical fluid extraction is not particularly limited.
- 1 part by weight of the supercritical fluid 0.001 to 100 parts by weight, preferably 1 220 parts by weight.
- a supercritical fluid extraction device is used for supercritical fluid extraction.
- the extraction tank temperature and extraction tank pressure used for supercritical fluid extraction must exceed the critical temperature and critical pressure, respectively, but there is no particular upper limit.
- the critical temperature and the critical pressure vary depending on the type of the compound.
- the temperature of the extraction tank is preferably 31.06 to; L0000, and 31 .:! To 60 is more preferable.
- the extraction tank pressure is 72.9 to 500 atm, more preferably 75 to 100 atm.
- the separation tank pressure is not particularly limited, but is preferably 1 to 500 atm, and more preferably 1 to L0000 atm.
- the temperature of the separation tank used for the supercritical fluid extraction is not particularly limited, but is preferably 127.16 to 100, more preferably -80 to 20.
- the extraction time is Although there is no limitation, 1 minute to 100 hours is preferable, and 20 minutes to 5 hours is more preferable.
- the extraction liquid can be obtained by changing the temperature and pressure of the separation tank, the filler, and the like.
- the method for separating the extract include an isothermal / decompression method, an isothermal / gas-liquid separation method, an isobaric / heating method, an isobaric / cooling method, and an adsorption method.
- the extract can be obtained as a solid or liquid substance in the separation tank, or as an entrainer solution when an entrainer is used.
- the plant extract of the present invention is obtained by subjecting an extract obtained from the plant by an extraction method such as solvent extraction or supercritical fluid extraction to a further concentration or drying method, a purification method, or the like. Is also good.
- Concentration or drying methods include heat concentration, freeze concentration, reverse osmosis concentration, vacuum concentration, freeze drying, natural drying, hot air drying, ventilation drying, blast drying, spray drying, vacuum drying, solar drying, vacuum drying, and spray drying. , Fluidized-bed drying, foam-bed drying, drum drying, and other film drying methods, ultrasonic drying method, electromagnetic wave drying method, etc., and reduced pressure concentration method, spray drying method, and freeze drying method are preferably used.
- a method for preventing inactivation of the active ingredient for example, addition of an antioxidant, a preservative, or the like, adjustment of a heating temperature, and the like may be performed.
- the extract of the plant of the present invention is more effective for extracting residues obtained by extracting the active ingredient from the plant of the present invention by various solvent extraction, supercritical fluid extraction, etc. under conditions where extraction is difficult or difficult. It may be prepared by extraction with various solvents, supercritical fluid extraction, etc. under the conditions under which the components are extracted.
- the residue obtained after extracting the dried product of the plant of the present invention with an aqueous medium is preferably Extraction with alcohol, hydrous alcohol or aliphatic ketone is preferred.
- the amino sugar or a salt thereof includes, for example, dalcosamine, galactosamine, neuraminic acid, N-acetyldarcosamine, N-acetylgalactosamine, N-acetylneuraminic acid, N-glycolylneuraminic acid, or These salts are exemplified, but dalcosamine or a salt thereof is preferably used.
- the salt in the amino sugar salt include hydrochloride, sulfate, phosphate and the like.
- Darcosamine can be obtained, for example, by deproteinizing the shell of crustaceans, hydrolyzing chitin obtained by decalcification with concentrated hydrochloric acid, deacetylating, decolorizing, filtering, concentrating, separating, washing, and drying.
- a commercially available product for example, Darcosamine KHF manufactured by Kyowa High Foods Co., Ltd. may be used.
- Examples of the salt in the salt of dalcosamine include hydrochloride, sulfate (eg, dalcosamine 6-sulfate), phosphate (eg, darcosamine 6-phosphate).
- glycosaminodalican examples include hyaluronic acid, chondroitin, chondroitin sulfate, keratan sulfate, heparin, heparan sulfate, dermafen sulfate, and salts thereof, and chondroitin sulfate or a salt thereof. It is preferably used.
- Examples of the salt in the glycosaminodalican salt include a sodium salt, a potassium salt, a calcium salt and the like.
- Chondroitin sulfate is a type of mucopolysaccharide distributed generally in animal connective tissues, mainly in cartilage, and binds to proteins in tissues and exists as proteodalican.
- the chondroitin sulfate may be used in a purified form or in the form of proteodalican, cartilage extract or dried cartilage powder.
- the neutral salt method, alkali method, and enzymatic method Extraction may be performed according to a known method such as a photoclave method, for example, the method described in JP-A-2001-246702, the fat 'solid content and the like may be removed, and then drying may be performed.
- the protein is further deproteinized by using a protease, and a known method by alcohol precipitation, for example, a method described in JP-A-2001-246760
- chondroitin sulfate or a salt thereof can be obtained in a purified state.
- chondroitin sulfate or a salt thereof a commercially available one (for example, sodium chondroitin sulfate manufactured by Maruha Corporation) may be used.
- Examples of the salt in the salt of chondroitin sulfate include a sodium salt, a potassium salt and a potassium salt, and a sodium salt is preferably used.
- the arthritis to which the present invention can be applied is not particularly limited. Chlamydia arthritis, chronic absorbable arthritis, enteric arthritis, gonococcal arthritis, gout arthritis, Jacque arthritis, juvenile arthritis, lime arthritis, alkaptonic arthritis, It may be any of suppurative arthritis, osteoarthritis, shoulder periarthritis, arthritis due to excessive exercise load, rheumatoid arthritis, etc., but is particularly effective for rheumatoid arthritis.
- the prophylactic or therapeutic agent of the present invention comprises the plant of the present invention or an extract of the plant prepared by the method described above, and an amino sugar or a salt thereof and / or a daricosaminoglycan or a salt thereof (hereinafter also referred to as an active ingredient of the present invention). ) Is mixed with one or more pharmacologically acceptable carriers, if necessary, and produced by any method well known in the technical field of pharmaceutics.
- the active ingredient of the present invention includes a combination of the plant of the present invention or the extract of the plant and an amino sugar or a salt thereof, the plant of the present invention or the extract of the plant and Any combination of licosaminoglycan or a salt thereof, or a combination of the plant of the present invention or an extract of the plant, an amino sugar or a salt thereof, and glycosaminodalican or a salt thereof can be used. It is preferably a combination of a plant or an extract of the plant, an amino sugar or a salt thereof, and daricosaminodalican or a salt thereof.
- the prophylactic or therapeutic agent of the present invention may further contain components for preventing or treating other diseases, if necessary.
- any other components effective for preventing or treating arthritis may be added.
- ingredients that are effective in preventing or treating arthritis include, for example, boron, calcium, chromium, copper, magnesium, manganese, selenium, silicon, zinc, S-adenosylmethionine, collagen, collagen hydrolyzate, gelatin, Gelatin hydrolysates, bromelain, trypsin, chymotrypsin, papain, rutin, oral tinoids, flavonoids, antioxidant vitamins, a-linolenic acid, eicosapenic acid, bosperia, capsaicin, jacklow, devil's black, fibar fever , Ginger, nettles, niacinamide, Yuichi Merrick and curcumin.
- the other active ingredient that is effective for the prevention or treatment of arthritis may be a purified product, or a content or extract of the component.
- the administration route of the prophylactic or therapeutic agent of the present invention is desirably effective in preventing or treating arthritis, and may be oral administration or parenteral administration such as intravenous administration.
- Dosage forms include, for example, tablets, powders, granules, pills, capsules, suspensions, emulsions, elixirs, syrups, solutions, dips, decoctions, extracts, tinctures, liquid extracts, etc.
- parenteral preparations such as oral preparations, injection preparations, drops, creams, suppositories and the like may be used, but they are suitably used as oral preparations.
- additives such as excipients, binders, disintegrants, lubricants, dispersants, suspensions, emulsifiers, diluents, buffers, antioxidants, and bacteria inhibitors Can be used.
- the dosage form for oral administration is tablets, powders, granules, etc., sugars such as lactose, sucrose, glucose, sucrose, mannitol, sorbitol, starch such as potato, wheat, corn, calcium carbonate, calcium sulfate, Inorganic substances such as sodium bicarbonate and sodium chloride, excipients such as crystalline cellulose, plant powders such as corn powder and gentian powder, starch, agar, gelatin powder, crystalline cellulose, carmellose sodium, carmellose calcium, calcium carbonate Disintegrators such as sodium bicarbonate and sodium alginate, lubricants such as magnesium stearate, talc, hydrogenated vegetable oils, macrogol, silicone oil, polyvinyl alcohol, hydroxypropyl cellulose, methylcellulose, ethylcellulose, cal
- the preparation can be prepared by adding a binder such as melose, gelatin, starch paste, a surfactant such as fatty acid ester, or a plasticizer such as
- the dosage form of the oral preparation is a liquid preparation such as a syrup, sugars such as water, sucrose, sorbitol, and fructose, glycols such as polyethylene glycol and propylene glycol, sesame oil, oil of olive oil, Diluents for oils such as soybean oil, preservatives such as p-hydroxybenzoic acid esters, paraoxybenzoic acid derivatives such as methyl parahydroxybenzoate, preservatives such as sodium benzoate, flavoring agents such as strawberry flavor and peppermint
- a liquid preparation such as a syrup
- sugars such as water, sucrose, sorbitol, and fructose
- glycols such as polyethylene glycol and propylene glycol
- sesame oil oil of olive oil
- Diluents for oils such as soybean oil
- preservatives such as p-hydroxybenzoic acid esters, paraoxybenzoic acid derivatives such as methyl parahydroxybenzoate
- preservatives such as sodium benzo
- extracts, tinctures, liquid extracts, etc. suitable for oral administration include extracts obtained by extracting the plant of the present invention with, for example, water, ethanol, a mixed solution of water and ethanol, and the like. Alternatively, it can be prepared by concentration.
- Formulations suitable for parenteral administration include those of the present invention, which are preferably isotonic with the blood of the recipient. It consists of a sterile aqueous preparation containing the active ingredient.
- a solution for injection is prepared using a carrier comprising a salt solution, a glucose solution or a mixture of a salt solution and a glucose solution.
- auxiliary ingredients may be added.
- the dosage and frequency of administration of the prophylactic or therapeutic agent of the present invention will vary depending on the dosage form, the age and weight of the patient, the nature or severity of the condition to be treated, etc.
- As the dry weight of the plant or its extract, and as an anosugar or a salt thereof and / or glycosaminodalican or a salt thereof preferably from 0.001 to 50 g, more preferably from 0.1 to 50 g. 05-: LO g is administered once or several times a day.
- parenteral administration such as intravenous administration
- the amount of the plant of the present invention or the extract of the plant, the amino sugar or a salt thereof and Z or glycosaminodalican or a salt thereof per adult per adult is preferred.
- Is 0.005 to 50 g, more preferably 0.002 to: L 0 g is administered once to several times a day.
- the administration period is usually 1 week to 10 years, preferably 1 month to 5 years.
- the prophylactic or therapeutic agent of the present invention can be used not only for humans but also for non-human animals (hereinafter also referred to as non-human animals).
- the dose and frequency of administration are as follows: per kg of body weight of the non-human animal, the dry weight of the plant of the present invention or the extract of the plant; 0.02 to 10 g, more preferably 0.01 to 2 g, of nodalican or a salt thereof is administered once or several times a day.
- the administration period is usually 1 week to 5 years, preferably 2 weeks to 2 years.
- the composition ratio of the plant of the present invention or the dried product of the plant extract to an amino sugar or a salt thereof and / or glycosaminodalican or a salt thereof is by weight. 1: 100 to 100: 1, preferably 1:50 to 50: 1, particularly preferably 10: 1 to 1:10.
- the prophylactic or therapeutic agent of the present invention may be prepared so that the active ingredient of the present invention is contained in the same preparation.However, separate preparations are manufactured and used as kit-form preparations. Is also good.
- the active ingredient of the present invention is contained in the kit, it is not always necessary to include the plant of the present invention or the extract of the plant in each of the preparations constituting the kit. May be any combination.
- the combination of the preparations constituting the kit include a preparation containing the plant of the present invention or an extract of the plant, and a preparation containing an amino sugar or a salt thereof and / or a preparation containing a daricosaminodarican or a salt thereof , But is not limited thereto.
- each of the preparations contained in the kit may exist in any state as long as they exist separately.
- each preparation may be packaged separately or may be mixed in the same container.
- each of the preparations contained in the kit is to be administered separately, it is desirable to administer it within a time when the active ingredient in the preparation has high efficacy in the body.
- all formulations are administered within 8 hours, preferably within 2 hours, per administration.
- the food and drink additive of the present invention can be prepared by the same method as the oral preparation of the present invention.
- Food and drink additives are usually mixed or dissolved with other food additives as necessary, and are processed and manufactured into, for example, powders, granules, pellets, tablets, and various liquid forms.
- the food or drink of the present invention contains the active ingredient of the present invention or the food or drink additive of the present invention in the food or drink. Except for the addition of, it can be processed and manufactured by using a general food and beverage manufacturing method.
- the food and drink of the present invention include, for example, fluidized bed granulation, stirring granulation, extrusion granulation, tumbling granulation, airflow granulation, compression molding granulation, crushing granulation, spray granulation, spray granulation, etc.
- Granulation method pan coating, fluidized bed coating, dry coating, etc. coating method, puff dry, excess steam method, foam matting method, expansion method such as microwave heating method, extrusion method using extrusion granulator and extruder etc. It can also be manufactured using such as.
- the food and drink of the present invention include juices, soft drinks, teas, lactic acid bacteria drinks, fermented milk, frozen desserts, dairy products such as butter, cheese, yogurt, processed milk, skim milk powder, ham, and so on.
- Meat products such as hamburgers, hamburgers, bamboo rings, fish paste products such as fried fish, egg rolls, egg products such as egg tofu, cookies, jelly, chewing gum, candy, snacks and other confectionery, breads, ⁇ , Pickles, incense products, dried fish, boiled fish, tsukudani, salted products, soups, seasonings, etc.
- the food and drink of the present invention may be in the form of, for example, powdered food, sheet food, bottled food, canned food, retort food, capsule food, tablet food, liquid food, drink, and the like.
- the food or drink of the present invention can also be used as a health food or a functional food having an effect of preventing or treating arthritis.
- the foods and drinks or food and drink additives of the present invention include food additives generally used in foods and drinks, such as sweeteners, coloring agents, preservatives, thickening stabilizers, antioxidants, coloring agents, and bleaching agents. , Fungicides, gum bases, bitters, enzymes, brighteners, acidulants, seasonings, emulsifiers, enhancers, manufacturing agents, flavors, spice extracts and the like may be added.
- Sweeteners include aspartame, kanzo, stevia, xylose, lacan Power, etc.
- coloring agent examples include carotenoids, cocoon pigments, flavonoids, caramel pigments, sicon pigments, spirulina pigments, chlorophyll, purple potato pigments, purple potato pigments, perilla pigments, and blueberry pigments.
- preservatives examples include sodium sulfite, benzoic acids, udo extract, egonogi extract, potato extract, sorbic acids, propionic acids, and the like.
- thickening stabilizer examples include gums such as gum arabic and xanthan gum, alginic acids, chitin, chitosan, extract of idachialoe, guar gum, hydroxypropylcellulose, sodium caseinate, corn starch, carboxymethylcellulose, Gelatin, agar, dextrin, methylcellulose, polyvinyl alcohol, microfibrous cellulose, microcrystalline cellulose, seaweed cellulose, sodium polyacrylate, sodium polyphosphate, carrageenan, yeast cell wall, konjac extract, nadu deco, mannan, etc. Is raised.
- gums such as gum arabic and xanthan gum, alginic acids, chitin, chitosan, extract of idachialoe, guar gum, hydroxypropylcellulose, sodium caseinate, corn starch, carboxymethylcellulose, Gelatin, agar, dextrin, methylcellulose, polyvinyl alcohol, microfibrous cellulose, microcrystalline cellulose, sea
- Antioxidants include vitamin C, sodium ethylenediaminetetraacetate, ethylenediaminetetraacetate, erythorbic acid, oryzanol, catechin, quercetin, clove extract, enzyme-treated rutin, apple extract, sesame oil extract, dibutyl Hydroxytoluene, fennel extract, horseradish extract, seri extract, cherries extract, tempeh extract, dokudami extract, tocotrienols, tocopherols, rapeseed oil extract, green coffee bean extract, sunflower seeds, Ferulic acid, butylhydroxyanisole, Blueberry monoleaf extract, Propolis extract, Hego's ginkgo extract, Hesperetin, Pepper extract, Balsam extract, Gallic acid, Bayberry extract, Eucalyptus extract, Rose Marie extract etc. It is.
- the coloring agent include sodium nitrite.
- bleaching agent examples include sodium sulfite.
- fungicides examples include orthophenylphenol and the like.
- isoalpha monobitter acid caffeine, potato mushroom extract, kina extract, yellowfin extract, gentian extract, spice extract, enzyme-treated naringin, jamaican cassia extract, deobokumin , Naringin, squid extract, two-spotted extract, hinoki sorghum extract, himematsutake extract, borapet, methylthioadenosine, litchi extract, olive tea, daidai extract, hop extract, mugwort extract, etc.
- Enzymes include amylase, trypsin, rennet, lactic acid bacteria, etc.
- Examples of the brightener include shiro wax, mokurou and the like.
- Examples of the acidulant include adipic acid, itaconic acid, cunic acid, succinic acid, sodium acetate, tartaric acid, carbon dioxide, lactic acid, phytic acid, fumaric acid, malic acid, and phosphoric acid.
- Seasonings include amino acids such as asparagine, aspartic acids, glutamic acid, daltamin, alanine, isoleucine, glycine, serine, cystine, tyrosine, oral isin, proline, etc.
- Nucleic acids such as sodium, liponucleotide calcium, liponucleotide sodium, etc., organic acids such as citric acid and succinic acid, potassium chloride, salt water in low salt sodium chloride, crude seawater potassium chloride, whey salt, tripotassium phosphate, hydrogen phosphate Dipotassium, potassium dihydrogen phosphate, disodium hydrogen phosphate, sodium dihydrogen phosphate, trisodium phosphate, chlorella extract and the like.
- emulsifier examples include fatty acid monoglyceride and sorbin fatty acid ester.
- Enhancers include zinc salts, vitamin C, various amino acids, 5-adenylic acid, iron chloride, hesperidin, various calcined calcium, various uncalcined calcium, dibenzoylthiamine, calcium hydroxide, calcium carbonate, thiamine hydrochloride, Dunalier Lacarotene, tocopherol, nicotinic acid, carrot carotene, palm oil carotene, calcium pantothenate, vitamin A, hydroxyproline, calcium dihydrogen pyrophosphate, ferrous pyrophosphate, ferric pyrophosphate, ferritin, heme iron, menaquinone, Folic acid, riboflavin and the like.
- Manufacturing agents include processing aids such as acetone and ion-exchange resin, fig leaf extract, rice ash extract, kaolin, glycerin fatty acid ester, mulberry extract, bone ash, perilla extract, ginger extract, various tannins , Puffy extract, grape seed extract, ethanol and the like.
- processing aids such as acetone and ion-exchange resin, fig leaf extract, rice ash extract, kaolin, glycerin fatty acid ester, mulberry extract, bone ash, perilla extract, ginger extract, various tannins , Puffy extract, grape seed extract, ethanol and the like.
- fragrance examples include the fragrances described above.
- the spice extract examples include pepper extract, garlic extract and the like.
- the amount of the active ingredient or food or drink additive of the present invention added to the food or drink of the present invention is appropriately selected according to the type of food or drink, the effect expected from ingestion of the food or drink, and the like.
- the amount of the plant or the plant extract dry amount, and the amino sugar or a salt thereof and the amino or glycosaminodalican or a salt thereof are usually 0.01 to 100% by weight, preferably 0.1 to 10% by weight. It is added so as to contain 0% by weight.
- the food or drink of the present invention varies depending on the form of ingestion, the age and weight of the ingestor, etc., but the amount of the plant of the present invention or the dry amount of the extract of the plant, amino sugar or As the salt and / or glycosaminoglycan or a salt thereof, preferably 0.001 to 50 g, more preferably 0.005 to; LO g is increased once or several times a day.
- the period of ingestion is usually 1 day to 10 years, preferably 2 weeks to 5 years.
- the food and drink of the present invention may be prepared so that the active ingredient of the present invention is contained in the same food and drink, or may be manufactured as a food and drink set.
- the active ingredient of the present invention is contained in the set, it is not always necessary to include the plant of the present invention or the extract of the plant in each of the foods and drinks constituting the set. May be any combination.
- Examples of the combination of each food and drink in the food and drink set include, for example, a food or drink containing the plant of the present invention or the extract of the plant, a food or drink containing an amino sugar or a salt thereof, and / or glycosaminodalican or Combinations of foods and drinks containing the salt can be given, but are not limited thereto.
- Each food and drink included in the food and drink set may exist in any state as long as they exist separately.
- each food or drink may be separately packaged, or may be mixed in the same container.
- the feed additive of the present invention can be prepared by the same method as the oral preparation of the present invention.
- the feed additive is usually mixed or dissolved with other feed additives as needed, and is processed and manufactured into, for example, powders, granules, pellets, tablets, and various liquids.
- the feed of the present invention may be a feed for animals belonging to any of mammals, birds, reptiles, amphibians or fish, as long as the feed contains the active ingredient of the present invention, for example, dogs, cats, rats, etc.
- Feed for pets feed for mammals such as livestock feed such as sea bream and bush, feed for birds such as feed for poultry such as chickens and turkeys, and feed for fish such as feed for farmed fish such as Thailand and hamachi. It is preferably used as feed for mammals.
- the feed of the present invention can be processed and manufactured by using a general feed manufacturing method except that the active ingredient of the present invention or the feed additive of the present invention is added to the feed.
- feed raw materials include cereals, alga, vegetable oil cake, animal feed raw materials, other feed raw materials, purified products, and mixtures thereof.
- Grains include, for example, my mouth, wheat, barley, oats, oats, brown rice, buckwheat, bubbles, cane, fins, corn, soybeans, and the like.
- Algae include, for example, rice bran, defatted rice bran, bran, ground powder, wheat, germ, wheat bran, screening, pellets, corn bran, corn germ, and the like.
- Vegetable oil cakes include, for example, soybean oil cake, kinako, linseed oil cake, cottonseed oil cake, peanut oil cake, safflower oil cake, palm oil cake, palm oil cake, sesame oil cake, sunflower oil cake, and rape oil. I will give you the residue, kapok oil residue, mustard oil residue, etc. It is.
- Animal feed ingredients include, for example, northern meal, imported meal, whole meal, coastal meal, fish meal, fish solvable, meat meal, meat-and-bone meal, blood meal, decomposed hair, bone meal, livestock processing by-products, feather meal, silkworm , Skim milk powder, casein, dried whey and the like.
- feed ingredients include plant foliage such as Alf Alpha, Hay Cube, Alf Alpha Leaf Meal, and False Acacia Powder; corn processing industrial by-products such as corn gluten meal, corn gluten feed, corn staple liquor, and starch processing such as starch.
- corn processing industrial by-products such as corn gluten meal, corn gluten feed, corn staple liquor, and starch processing such as starch.
- purified products include proteins such as casein and albumin, amino acids, carbohydrates such as starch, cellulose, sucrose, and glucose, minerals, and vitamins.
- the feed of the present invention is, for example, fluidized bed granulation, stirring granulation, and extrusion.
- Granulation methods such as granulation, tumbling granulation, airflow granulation, compression molding granulation, crushing granulation, spray granulation, and spray granulation; coating methods such as pan coating, fluidized bed coating, and dry coating; It can also be produced by a puff drying method, an excess steam method, a foam matting method, an expansion method such as a microwave heating method, or an extrusion method using an extruder or an extruder.
- the amount of the active ingredient or feed additive of the present invention to be added to the feed of the present invention is appropriately selected depending on the type of feed, the effects expected from ingestion of the feed, and the like. Dry amount of the plant extract, and amino sugar or a salt thereof and Z Alternatively, glycosaminodalican or a salt thereof is usually added so as to contain 0.01 to 100% by weight, preferably 0.1 to 100% by weight.
- the feed of the present invention varies depending on the form of ingestion, the type of animal, the age and weight of the animal, etc., and the amount of the plant of the present invention or the dried amount of the plant extract per 1 kg of animal weight, and amino sugar Alternatively, as a salt thereof and Z or dalicosaminoglycan or a salt thereof, preferably 0.002 to 10 g, more preferably 0.01 to 2 g, is divided once or several times a day. Oral administration, that is, ingestion. The period of ingestion is usually 1 week to 5 years, preferably 2 weeks to 2 years.
- the feed additive of the present invention is used as an oral preparation for animals having an effect of preventing or treating arthritis in a subject who consumes the feed, at the same dosage and the same dosage period as that of the above-mentioned feed. May be administered.
- the animal feed of the present invention may be prepared so that the active ingredient of the present invention is contained in the same animal feed, or may be manufactured as a feed set.
- each feed constituting the set contains the plant of the present invention or the extract of the plant, and how each feed is prepared. May be any combination.
- the feed set combination include, for example, a feed containing the plant of the present invention or an extract of the plant, a feed containing an amino sugar or a salt thereof, and a feed containing a daricosaminodalican or a salt thereof. Combinations can be given, but are not limited to these.
- Each animal feed contained in the feed set may exist in any state as long as it exists separately.
- each animal feed may be separately packaged, or may be mixed in the same container.
- the active ingredient be administered within a time when it has high potency in the body. For example, ingest a whole feed within 8 hours, preferably within 2 hours.
- Extraction was performed by adding 10 L of distilled water to 1 kg of dried sweet tea powder (manufactured by Shihira Shoten) and stirring at room temperature for 1 hour. After separating into a filtrate and an extraction residue by filtration, 10 L of distilled water was added to the extraction residue, and the mixture was stirred again at room temperature for 1 hour to perform extraction again. A filtrate was obtained by filtration and mixed with the filtrate obtained above. The combined filtrate was concentrated overnight and evaporated and lyophilized to give 200 g of lyophilized powder.
- Extraction was started by adding 20 L of distilled water to 1 kg of the dried sweet tea powder and stirring at 40. The extraction was terminated when the absorbance at 313 nm of the solution obtained by diluting the extract to 1200 with distilled water reached 0.15. The filtrate was removed by filtration to obtain an extraction residue. To the residue was added 20 L of a 60% (v / v) aqueous ethanol solution, and the mixture was stirred at 40 to start extraction. The extraction was terminated when the absorbance at 3 13 nm of the solution obtained by diluting the extract to 1/200 with distilled water reached 0.22. The filtrate obtained by filtration was concentrated by an evaporator, and then lyophilized to obtain 70 g of a lyophilized powder.
- Example 3 The arthritis inhibitory effect was tested using a mouse collagen-induced arthritis model [Nature, 1980, Vol. 283, p. 666-668]. Lusriva Co., Ltd.) and the first administration of type 2 collagen, type 2 collagen (manufactured by Collagen Technology Training Company) and Freund's original adjuvant (Freund scomp lete adjuvant, manufactured by Jatron) Were mixed in equal amounts and emulsified with a homogenizer, and 100 1 per animal was intradermally administered to the ridge. One day after the first administration of type 2 collagen, a solution prepared by mixing equal amounts of type 2 collagen and complete Freund's adjuvant and emulsifying with a homogenizer was similarly used for the second administration of type 2 collagen. Was intradermally administered to the ridge.
- CE-2 % -Added CE-2, 1.0% by weight of dalcosamine (D_Darcosamine sulfate sodium dichloride, manufactured by Miyako Chemical Co., Ltd.) and chondroitin sulfate (sodium chondroitin sulfate, manufactured by Maruha Corporation) to mice in Group 3 ) was added to 1.0% by weight of CE-2, and the mice of Group 4 were 0.25% by weight of the sweet tea extract prepared in Example 2, 0.5% by weight of dalcosamine, and chondroitin sulfate. Was added, and each of them was ingested with 0.5% by weight of CE-2. The untreated group to which type 2 collagen was not administered received CE-2.
- D_Darcosamine sulfate sodium dichloride manufactured by Miyako Chemical Co., Ltd.
- chondroitin sulfate sodium chondroitin sulfate
- the degree of arthritis was scored by the following index. 0 point: no symptom, 1 point: one finger swelling, or hand (foot) neck (mild) swelling, 1 point: 1 to 3 fingers swelling, Or hand (foot) neck swelling, 3 points: 3-5 fingers swelling 10 hands (foot) neck No swelling, 4 points: All fingers swelling + hand (foot) neck swelling, scored from 0 to 4 points.
- Table 1 shows the results of the arthritis score.
- Group 1 0.00 ⁇ 0.00 6.65 ⁇ 0.48 ".70 ⁇ 0.56 13.30 ⁇ 0.59
- Group 2 Sweet tea extract 0.5%) 0.00 ⁇ 0.00 5.44 ⁇ 0.51 10.1 1 ⁇ 0.75 1 1.56 ⁇ 0.72
- Group 3 Gercosamine 1.0%) 0.00 ⁇ 0.00 5.60 ⁇ 0.41 10.65 ⁇ 0.64 12.30 ⁇ 0.60
- groups 2 and 3 showed a weaker suppression of the increase in the arthritis score over time as compared to group 1.
- group 4 fed with a half amount of the sweet tea extract in the second group and the half amount of the glucosamine and chondroitin sulfate in the third group, the arthritis score with respect to the time was compared with the groups 2 and 3. The increase was markedly suppressed.
- Example 5 The freeze-dried powder produced in Example 2 9.8 g Darcosamine (manufactured by Miyako Chemical Co., Ltd.) 19.6 g Chondroitin sulfate (manufactured by Maruha Corporation) 19.6 g Paindex # 3 (manufactured by Matsutani Chemical Industry Co., Ltd.) 49 g Ferric pyrophosphate (iron source; Kokusan Chemical) 0.1 g foscar EFC (calcium source; Nikko Fine Products) lg Vitamin mix (Merck) Example 5
- Example 6 20 g of the prophylactic or therapeutic agent for arthritis prepared in Example 4 is dispersed in 180 ml of water to produce a beverage for preventing or treating arthritis.
- Example 6 20 g of the prophylactic or therapeutic agent for arthritis prepared in Example 4 is dispersed in 180 ml of water to produce a beverage for preventing or treating arthritis.
- Chondroitin sulfate (made by Maruha Corporation) 12 g
- a I N-76 mineral (Oriental Yeast) 3.5% by weight
- prevention of arthritis containing a plant belonging to the genus Hydrangea or an extract of the plant, and aV: chirp or a salt thereof and / or ⁇ -nonocosaminodalican or a salt thereof as an active ingredient.
- a therapeutic agent, or a food or drink, a food or drink additive, a feed or a feed additive for preventing or treating arthritis can be provided.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Polymers & Plastics (AREA)
- Engineering & Computer Science (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Mycology (AREA)
- Botany (AREA)
- Epidemiology (AREA)
- Animal Husbandry (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Dermatology (AREA)
- Organic Chemistry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physical Education & Sports Medicine (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicines Containing Plant Substances (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Fodder In General (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims
Priority Applications (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP04726828A EP1637151A1 (en) | 2003-04-11 | 2004-04-09 | Preventive or remedy for arthritis |
| US10/552,526 US20060193962A1 (en) | 2003-04-11 | 2004-04-09 | Preventive or remedy for arthritis |
| JP2005505375A JPWO2004091642A1 (ja) | 2003-04-11 | 2004-04-09 | 関節炎の予防または治療剤 |
| CA002521991A CA2521991A1 (en) | 2003-04-11 | 2004-04-09 | Arthritis preventing or treating agent |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2003107405 | 2003-04-11 | ||
| JP2003-107405 | 2003-04-11 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2004091642A1 true WO2004091642A1 (ja) | 2004-10-28 |
Family
ID=33295858
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/JP2004/005115 Ceased WO2004091642A1 (ja) | 2003-04-11 | 2004-04-09 | 関節炎の予防または治療剤 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20060193962A1 (ja) |
| EP (1) | EP1637151A1 (ja) |
| JP (1) | JPWO2004091642A1 (ja) |
| KR (1) | KR20050108423A (ja) |
| CN (1) | CN1771046A (ja) |
| CA (1) | CA2521991A1 (ja) |
| WO (1) | WO2004091642A1 (ja) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2006176460A (ja) * | 2004-12-24 | 2006-07-06 | Kanebo Ltd | 生薬配合組成物及びそれを含有する製剤 |
| JP2009173564A (ja) * | 2008-01-23 | 2009-08-06 | Yamasa Shoyu Co Ltd | 唾液分泌促進剤 |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100830746B1 (ko) * | 2000-12-23 | 2008-05-20 | 신준식 | 오적골, 우슬, 두충, 오가피, 고비 및 구판을 주성분으로 함유하는 의약조성물 및 이를 주성분으로 함유한 약학적 제제 |
| KR100759468B1 (ko) * | 2006-06-26 | 2007-10-04 | 한국생명공학연구원 | 자색 고구마로부터 분리된 자색 색소를 함유하는 통풍 예방및 치료용 조성물 |
| RU2467759C2 (ru) * | 2006-11-15 | 2012-11-27 | Артрайтис Рилиф Плас Лтд | Состав для местного использования и его применения |
| US8697138B2 (en) | 2007-03-28 | 2014-04-15 | Aker Biomarine As | Methods of using krill oil to treat risk factors for cardiovascular, metabolic, and inflammatory disorders |
| FI2144618T4 (fi) | 2007-03-28 | 2025-02-13 | Aker Biomarine Antarctic As | Biovaikuttavat krilliöljykoostumukset |
| CA2839075A1 (en) * | 2007-08-29 | 2009-03-05 | Aker Biomarine Asa | A new method for making krill meal |
| CN102335219A (zh) * | 2007-11-21 | 2012-02-01 | 客乐谐制药株式会社 | 芳香酶抑制剂 |
| US20090311238A1 (en) * | 2008-06-11 | 2009-12-17 | Crandall Wilson T | Topical composition and treatment method for cartilage damage |
| JP5602346B2 (ja) * | 2008-06-17 | 2014-10-08 | 株式会社ロッテ | ユーカリ抽出物の調製方法 |
| MX2012001568A (es) * | 2009-08-10 | 2012-04-02 | Stokely Van Camp Inc | Metodo para suspender un flavonoide en una bebida. |
| CN101822324B (zh) * | 2009-11-30 | 2012-06-20 | 上海可可庄进出口有限公司 | 一种用于护理宠物关节的食品及其制备方法 |
| CA2785646C (en) | 2009-12-29 | 2016-10-18 | Hill's Pet Nutrition, Inc. | Compositions including ginger for the amelioration or prevention of inflammatory conditions |
| KR102258773B1 (ko) * | 2011-07-26 | 2021-06-01 | 지엘팜텍주식회사 | 가금류의 생산성 개선을 위한 사료 조성물 |
| JP5990059B2 (ja) * | 2012-08-03 | 2016-09-07 | 花王株式会社 | StAR発現抑制剤 |
| AU2014203179C1 (en) | 2013-06-14 | 2017-05-04 | Aker Biomarine Antarctic As | Lipid extraction processes |
| CN103463624A (zh) * | 2013-09-22 | 2013-12-25 | 徐波 | 一种骨关节复合营养强化剂及其制备方法 |
| GB201400431D0 (en) | 2014-01-10 | 2014-02-26 | Aker Biomarine As | Phospholipid compositions and their preparation |
| RU2564841C1 (ru) * | 2014-09-03 | 2015-10-10 | Сергей Валерьевич Штерман | Функциональный пищевой продукт для поддержания здоровья суставов и связок |
| PT3256003T (pt) | 2015-02-11 | 2023-02-15 | Aker Biomarine Antarctic As | Processo de extração de lipídios |
| EP3256553A2 (en) | 2015-02-11 | 2017-12-20 | Aker Biomarine Antarctic AS | Lipid compositions |
| CN105394342B (zh) * | 2015-11-25 | 2019-07-02 | 江苏桑园圣树农业科技发展有限公司 | 一种饲用桑叶粉的制备方法 |
| US20170266130A1 (en) * | 2015-12-21 | 2017-09-21 | Script Essentials, Llc | Compositions, methods for making the compositions, and methods for treating joint disease |
| CN109771444A (zh) * | 2019-04-03 | 2019-05-21 | 哈尔滨北极神生物工程有限公司 | 蜂胶氨糖人参皂甙复合胶囊及制备方法 |
| CN111084301B (zh) * | 2019-12-30 | 2023-08-22 | 内江师范学院 | 一种桑叶提取物鱼饲料粘合剂及制备方法和应用 |
| KR102567940B1 (ko) * | 2022-03-18 | 2023-08-18 | 주식회사 마르켄9 | 기호성을 높힌 반려동물용 데일리 영양제 |
| CN120916647A (zh) * | 2023-04-19 | 2025-11-07 | 贝拉贝尔生物股份有限公司 | 包含粗齿绣球提取物或绣球酚作为有效成分的用于预防、改善或治疗关节炎的组合物 |
| CN119054786A (zh) * | 2024-08-08 | 2024-12-03 | 格莱德(福建)生物科技有限公司 | 一种能够有效活化宠物关节的宠物功能食品配方及其制备方法 |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH09503197A (ja) * | 1993-03-31 | 1997-03-31 | ニュートラマックス ラボラトリーズ,インコーポレイテッド | 結合組織の治療と回復のためのアミノ糖とグリコサミノグリカン組成物 |
| JP2001072582A (ja) * | 1999-09-07 | 2001-03-21 | Sunstar Inc | 機能性経口組成物 |
| JP2001078667A (ja) * | 1999-09-08 | 2001-03-27 | Fuso Chemical Co Ltd | グルコサミンを含有する飲料 |
| JP2003501381A (ja) * | 1999-06-07 | 2003-01-14 | ユニバーシティ・オブ・シェフィールド | 関節炎の処置 |
| JP2003081838A (ja) * | 2001-09-11 | 2003-03-19 | Rohto Pharmaceut Co Ltd | グルコサミン製剤 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2355196B (en) * | 1998-07-07 | 2004-06-09 | Coastside Bio Resources | Companion animal therapeutic treat |
| US6162787A (en) * | 1999-04-02 | 2000-12-19 | Immudyne, Inc. | Methods for treating arthritis using collagen type II, glucosamine chondroitin sulfate, and compositions |
| MXPA02009634A (es) * | 2000-03-31 | 2003-03-12 | Procter & Gamble | Composiciones cosmeticas, para aplicarse sin enjuagar, para aumentar el volumen del cabello. |
-
2004
- 2004-04-09 CA CA002521991A patent/CA2521991A1/en not_active Abandoned
- 2004-04-09 CN CNA2004800096992A patent/CN1771046A/zh active Pending
- 2004-04-09 KR KR1020057019263A patent/KR20050108423A/ko not_active Withdrawn
- 2004-04-09 EP EP04726828A patent/EP1637151A1/en not_active Withdrawn
- 2004-04-09 WO PCT/JP2004/005115 patent/WO2004091642A1/ja not_active Ceased
- 2004-04-09 JP JP2005505375A patent/JPWO2004091642A1/ja active Pending
- 2004-04-09 US US10/552,526 patent/US20060193962A1/en not_active Abandoned
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH09503197A (ja) * | 1993-03-31 | 1997-03-31 | ニュートラマックス ラボラトリーズ,インコーポレイテッド | 結合組織の治療と回復のためのアミノ糖とグリコサミノグリカン組成物 |
| JP2003501381A (ja) * | 1999-06-07 | 2003-01-14 | ユニバーシティ・オブ・シェフィールド | 関節炎の処置 |
| JP2001072582A (ja) * | 1999-09-07 | 2001-03-21 | Sunstar Inc | 機能性経口組成物 |
| JP2001078667A (ja) * | 1999-09-08 | 2001-03-27 | Fuso Chemical Co Ltd | グルコサミンを含有する飲料 |
| JP2003081838A (ja) * | 2001-09-11 | 2003-03-19 | Rohto Pharmaceut Co Ltd | グルコサミン製剤 |
Non-Patent Citations (2)
| Title |
|---|
| NAKAGIRI R. ET AL.: "Amacha (Hydrangeae Dulcis Folium) no kansetsuen yokusei sayo", NIPPON NOGEI GAKKAI KOEN YOSHISHU, vol. 2003, 5 March 2003 (2003-03-05), pages 58, XP002984691 * |
| SHIMODA H. ET AL.: "Amacha no isocoumarin thuberginol A oyobi kanren kagobutsu no men'eki chosetsu sayo", JOURNAL OF TRADITIONAL MEDICINES, vol. 15, no. 5, 1998, pages 296 - 297, XP002984692 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2006176460A (ja) * | 2004-12-24 | 2006-07-06 | Kanebo Ltd | 生薬配合組成物及びそれを含有する製剤 |
| JP2009173564A (ja) * | 2008-01-23 | 2009-08-06 | Yamasa Shoyu Co Ltd | 唾液分泌促進剤 |
Also Published As
| Publication number | Publication date |
|---|---|
| CA2521991A1 (en) | 2004-10-28 |
| KR20050108423A (ko) | 2005-11-16 |
| US20060193962A1 (en) | 2006-08-31 |
| JPWO2004091642A1 (ja) | 2006-07-06 |
| EP1637151A1 (en) | 2006-03-22 |
| CN1771046A (zh) | 2006-05-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2004091642A1 (ja) | 関節炎の予防または治療剤 | |
| KR100887854B1 (ko) | 관절염의 예방제 또는 치료제 | |
| JP5594819B2 (ja) | 脂質代謝改善用組成物 | |
| KR20190066478A (ko) | 람부탄 껍질 추출물을 유효성분으로 함유하는 항균 조성물 | |
| WO2004075905A1 (ja) | 筋肉増強剤および筋肉減衰の予防または治療剤 | |
| JP4401659B2 (ja) | インスリン分泌促進剤 | |
| JP2006045212A (ja) | 特定のキナ酸誘導体を含有する経口用組成物 | |
| JP4852683B2 (ja) | 大麦を発酵に付したものを有効成分とする血管新生阻害の作用を有する組成物 | |
| JP2009269832A (ja) | カルシトニン遺伝子関連ペプチド及びインスリン様成長因子−1の産生促進組成物 | |
| JP5248023B2 (ja) | カルシウム吸収促進組成物 | |
| JP2003252775A (ja) | Nk細胞活性化剤 | |
| JP6263820B1 (ja) | 飲食用組成物 | |
| JP2004244396A (ja) | TNF−α産生抑制剤 | |
| KR20110122961A (ko) | 헴프 종자 추출물을 포함하는 관절염 예방 및 치료용 조성물 | |
| JP2004099447A (ja) | コレステロール低減化ペプチド | |
| JP2004256403A (ja) | TNF−α産生抑制剤 | |
| JP2009084191A (ja) | 食欲抑制用薬理組成物 | |
| JP2022001597A (ja) | 組成物 | |
| JP2005089385A (ja) | リポキシゲナーゼ阻害剤 | |
| JP5192215B2 (ja) | 免疫賦活組成物 | |
| JP2004196696A (ja) | 関節炎の予防剤または治療剤 | |
| US20090263356A1 (en) | Anti-angiogenic composition comprising grain-derived component as active ingredient | |
| JP4104853B2 (ja) | 肝機能保護剤または改善剤 | |
| HK1083313A (en) | Preventive or remedy for arthritis | |
| JP2007091630A (ja) | 食品組成物及び経口用皮膚改善剤 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
| WWE | Wipo information: entry into national phase |
Ref document number: 2005505375 Country of ref document: JP |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 1020057019263 Country of ref document: KR |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 2006193962 Country of ref document: US Ref document number: 2521991 Country of ref document: CA Ref document number: 20048096992 Country of ref document: CN Ref document number: 10552526 Country of ref document: US |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 2004726828 Country of ref document: EP |
|
| WWP | Wipo information: published in national office |
Ref document number: 1020057019263 Country of ref document: KR |
|
| WWP | Wipo information: published in national office |
Ref document number: 2004726828 Country of ref document: EP |
|
| WWP | Wipo information: published in national office |
Ref document number: 10552526 Country of ref document: US |